What does this research mean for the field?

Neoadjuvant therapy provides a significant overall survival benefit for borderline resectable pancreatic cancer, but in strictly resectable disease, it improves disease-free survival and pathological outcomes without demonstrating a definitive overall survival advantage. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.NEUTRAL.

What question did this study set out to answer?

This review evaluates evidence comparing neoadjuvant therapy versus immediate surgery in operable pancreatic ductal adenocarcinoma.

April 25, 2026CancersOpen Access

Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses

View Full Paper

Ask AI

Bookmark

Authors

MGMichele Ghidini GIGiuseppe Ietto LDLorenzo Dottorini

Discussion

Member takes

Overview

Umbrella review compares neoadjuvant therapy and immediate surgery impact on survival in operable pancreatic cancer, indicating individualized treatment decisions are needed.

Key Points

This review evaluates evidence comparing neoadjuvant therapy versus immediate surgery in operable pancreatic ductal adenocarcinoma.
Conducted an umbrella review of systematic reviews and meta-analyses assessing neoadjuvant chemotherapy/chemoradiotherapy in resectable pancreatic cancer.
Searched databases including MEDLINE, Embase, and Cochrane Library for studies published until November 2025.
Appraised methodological quality using AMSTAR-2 and ROBIS, quantified overlap among studies, and graded evidence credibility.
No definitive overall survival benefit for neoadjuvant therapy compared to upfront surgery was found in strictly resectable PDAC (HR approximately 0.85, 95% CI 0.68–1.05).
Neoadjuvant therapy significantly improved overall survival in pooled resectable and borderline populations (HR approximately 0.66, 95% CI 0.52–0.85).
Neoadjuvant therapy increased rates of R0 resection and node-negative outcomes while showing treatment-related attrition and varied resection rates.

Cite This Study

Ghidini et al. (2026) studied this question.

synapsesocial.com/papers/69ec5b6088ba6daa22dace09 https://doi.org/10.3390/cancers18091344

View Full Paper

Ask AI

Bookmark

April 25, 2026CancersOpen Access

Upfront Chemotherapy Versus Immediate Surgery for Operable Pancreatic Cancer: An Umbrella Review of Meta-Analyses

View Full Paper

Ask AI

Bookmark

Authors

MGMichele Ghidini GIGiuseppe Ietto LDLorenzo Dottorini

Discussion

Member takes

Overview

Umbrella review compares neoadjuvant therapy and immediate surgery impact on survival in operable pancreatic cancer, indicating individualized treatment decisions are needed.

Key Points

This review evaluates evidence comparing neoadjuvant therapy versus immediate surgery in operable pancreatic ductal adenocarcinoma.
Conducted an umbrella review of systematic reviews and meta-analyses assessing neoadjuvant chemotherapy/chemoradiotherapy in resectable pancreatic cancer.
Searched databases including MEDLINE, Embase, and Cochrane Library for studies published until November 2025.
Appraised methodological quality using AMSTAR-2 and ROBIS, quantified overlap among studies, and graded evidence credibility.
No definitive overall survival benefit for neoadjuvant therapy compared to upfront surgery was found in strictly resectable PDAC (HR approximately 0.85, 95% CI 0.68–1.05).
Neoadjuvant therapy significantly improved overall survival in pooled resectable and borderline populations (HR approximately 0.66, 95% CI 0.52–0.85).
Neoadjuvant therapy increased rates of R0 resection and node-negative outcomes while showing treatment-related attrition and varied resection rates.

Cite This Study

Ghidini et al. (2026) studied this question.

synapsesocial.com/papers/69ec5b6088ba6daa22dace09 https://doi.org/10.3390/cancers18091344

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark